journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/30218541/impact-of-clone-size-with-a-single-cytogenetic-abnormality-on-the-revised-international-prognostic-scoring-system-in-myelodysplastic-syndromes
#1
LETTER
Omar Alkharabsheh, Salwa S Saadeh, Mrinal S Patnaik, Hassan Alkhateeb, Naseema Gangat, Kebede H Begna, William J Hogan, Patricia T Greipp, Rong He, Phuong L Nguyen, Mark R Litzow, Aref Al-Kali
No abstract text is available yet for this article.
September 15, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30218462/an-unanticipated-finding-on-peripheral-smear-blue-green-crystals-of-impeding-death
#2
Eric Sin, Adam J Korus, Alexandra Patterson, George Psevdos
No abstract text is available yet for this article.
September 15, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30218454/the-american-cancer-patients-first-plan-to-reduce-drug-prices-a-critical-assessment
#3
Hagop Kantarjian, Donald W Light, Vivian Ho
No abstract text is available yet for this article.
September 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30218444/allogeneic-stem-cell-transplantation-following-relapse-post-autologous-stem-cell-transplantation-in-adult-patients-with-acute-myeloid-leukemia-a-retrospective-analysis-of-537-patients-from-the-acute-leukemia-working-party-of-the-ebmt
#4
Maximilian Christopeit, Myriam Labopin, Norbert-Claude Gorin, Francesco Saraceni, Jakob Passweg, Edouard Forcade, Johan Maertens, Maria Teresa Van Lint, Alberto Bosi, Dietger Niederwieser, Gerhard Ehninger, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry and. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38...
September 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30203558/the-sickle-cell-disease-implementation-consortium-translating-evidence-based-guidelines-into-practice-for-sickle-cell-disease
#5
LETTER
Lisa D DiMartino, Ana A Baumann, Lewis L Hsu, Julie Kanter, Victor R Gordeuk, Jeffrey Glassberg, Marsha J Treadwell, Cathy L Melvin, Joseph Telfair, Lisa M Klesges, Allison King, Ted Wun, Nirmish Shah, Robert W Gibson, Jane S Hankins
No abstract text is available yet for this article.
September 10, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30203505/risk-of-red-cell-exposure-to-the-water-anomaly-upon-blood-unit-cold-storage
#6
LETTER
Dan Arbell, Moshe Gertzulin, Orly Zelig, Tanja Rasmusen, Gregory Barshtein, Saul Yedgar
No abstract text is available yet for this article.
September 10, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30203419/lineage-switch-from-acute-myeloid-leukaemia-to-t-cell-myeloid-mixed-phenotype-acute-leukaemia-first-report-of-an-adult-case
#7
LETTER
Brian P Hanley, Eva Yebra-Fernandez, Renuka Palanicawandar, Eduardo Olavarria, Kikkeri N Naresh
No abstract text is available yet for this article.
September 10, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30194866/sequential-hla-haploidentical-transplantation-utilizing-post-transplantation-cyclophosphamide-for-gvhd-prophylaxis-in-high-risk-and-relapsed-refractory-aml-mds
#8
Alessia Fraccaroli, Dusan Prevalsek, Susanne Fritsch, Sarah Haebe, Veit Bücklein, Christoph Schulz, Max Hubmann, Hans-Joachim Stemmler, Georg Ledderose, Andreas Hausmann, Christoph Schmid, Johanna Tischer
This study evaluates the role of sequential therapy in HLA-haploidentical transplantation (haplo-HSCT) of high-risk, relapsed/refractory AML/MDS. We analyzed the course of 33 adults with active disease at time of transplantation (AML n=30; MDS n=3; median age 58 years, range: 32-71). Sequential therapy consisted of cytoreductive chemotherapy (FLAMSA n=21; clofarabine n=12) applied shortly prior to reduced intensity conditioning for T-cell-replete haplo-HSCT using post-transplantation cyclophosphamide as GvHD prophylaxis...
September 8, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30194770/utility-and-prognostic-value-of-18-f-fdg-positron-emission-tomography-computed-tomography-scans-in-patients-with-newly-diagnosed-multiple-myeloma
#9
Mohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, Martha Q Lacy, Morie A Gertz, Angela Dispenzieri, David Dingli, Eli Muchtar, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET-CT abnormalities. Patients (N=313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions...
September 8, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30187944/locally-produced-cd19-car-t-cells-leading-to-clinical-remissions-in-medullary-and-extramedullary-relapsed-acute-lymphoblastic-leukemia
#10
Elad Jacoby, Bella Bielorai, Abraham Avigdor, Orit Itzhaki, Daphna Hutt, Vered Nussboim, Amilia Meir, Adva Kubi, Michal Levy, Dragoslav Zikich, Li-At Zeltzer, Karin Brezinger, Jacob Schachter, Arnon Nagler, Michal J Besser, Amos Toren
Autologous CD19 chimeric-antigen receptor (CAR) T cells demonstrated remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (R/R ALL). Here, we report results from a phase 1b/2 study of in-house produced CD19 CAR with a CD28 costimulatory domain. Twenty-one patients with R/R ALL were enrolled, and 20 infused. The median age was 11 years (range, 5-48). Patients had a median of 4 prior regimens, including blinatumomab in six and prior stem-cell transplantation in ten. Eight patients had extramedullary (EM) leukemic involvement, and prior to lymphodepletion and CAR 7 had active lesions, a group underrepresented in previous trials...
September 6, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30187942/thrombopoietin-level-predicts-response-to-treatment-with-eltrombopag-and-romiplostim-in-immune-thrombocytopenia
#11
Hanny Al-Samkari, David J Kuter
Thrombopoietin receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), but predicting clinical response to TPO-RAs before initiation is not possible. To determine whether endogenous thrombopoietin (TPO) levels predict treatment response to TPO-RAs we performed a retrospective analysis of ITP patients with known baseline TPO levels who received TPO-RAs. Data was collected for ITP patients with a baseline TPO level treated with eltrombopag or romiplostim. Multiple logistic regression was used to model the probability of three classes of treatment response (overall, moderate, and superior) based on TPO level; receiver operating characteristic (ROC) analysis was performed to identify optimal TPO thresholds for response; correlations between TPO level and various response characteristics were analyzed...
September 6, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30187935/a-dose-ranging-study-of-ticagrelor-in-children-aged-3-17-years-with-sickle-cell-disease-a-two-part-phase-2-study
#12
Lewis L Hsu, Sharada Sarnaik, Suzan Williams, Carl Amilon, Jenny Wissmar, Anders Berggren
Antiplatelet treatment is a potential therapeutic approach for sickle cell disease (SCD). Ticagrelor inhibits platelet aggregation and is approved for adults with acute coronary syndrome and following myocardial infarction. HESTIA1 (NCT02214121) was a two-part, phase 2 dose-finding study generating ticagrelor exposure, platelet inhibition, and safety data in children with SCD (3-17 years). In Part A (n = 45), patients received two ticagrelor single doses, 0.125 to 2.25 mg/kg (washout ≥7 days), then 7 days of twice-daily (bid) dosing with 0...
September 6, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30187933/genotype-phenotype-correlation-and-risk-stratification-in-a-cohort-of-123-hereditary-stomatocytosis-patients
#13
Andolfo Immacolata, Russo Roberta, Rosato Eleni Barbara, Manna Francesco, Gambale Antonella, Carlo Brugnara, Iolascon Achille
Hereditary stomatocytoses (HSt) are a wide spectrum of hemolytic anemias in which the erythrocyte membrane cation permeability is increased. Dehydrated hereditary stomatocytosis is the most frequent among hereditary stomatocytoses. It is caused by missense mutations in PIEZO1 and KCNN4 genes. We described 123 patients enrolled in our Genetic Unit from 2013 to 2017. Overall HSt subjects exhibit macrocytic mild anemia. We found that PIEZO1 is the most frequent mutated gene within our families (47% of pedigrees)...
September 6, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30184257/centrifugation-free-washing-reduces-buildup-of-potassium-and-free-hemoglobin-in-washed-red-blood-cells-after-the-procedure
#14
LETTER
Eszter Vörös, Madeleine Lu, Dalia Lezzar, Sergey S Shevkoplyas
No abstract text is available yet for this article.
September 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30184246/rituximab-bendamustine-and-cytarabine-r-bac-in-patients-with-relapsed-refractory-aggressive-b-cell-lymphoma
#15
LETTER
Maria Chiara Tisi, Rossella Paolini, Francesco Piazza, Erika Ravelli, Cristina Tecchio, Roberto Sartori, Barbara Famengo, Emanuele Stefano Giovanni D'Amore, Giuseppe Carli, Omar Perbellini, Eros Di Bona, Marco Ruggeri, Carlo Visco
No abstract text is available yet for this article.
September 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30178891/thsna-2018-summit-abstract-proceedings
#16
(no author information available yet)
No abstract text is available yet for this article.
September 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30160789/multicenter-randomized-trial-of-arsenic-trioxide-and-realgar-indigo-naturalis-formula-in-pediatric-patients-with-acute-promyelocytic-leukemia-interim-results-of-the-scclg-apl-clinical-study
#17
Ming-Hua Yang, Wu-Qing Wan, Jie-Si Luo, Min-Cui Zheng, Ke Huang, Li-Hua Yang, Hui-Rong Mai, Jian Li, Hui-Qin Chen, Xiao-Fei Sun, Ri-Yang Liu, Guo-Hua Chen, Xiaoqin Feng, Zhi-Yong Ke, Bin Li, Yan-Lai Tang, Li-Bin Huang, Xue-Qun Luo
Intravenous arsenic trioxide (ATO) has been adopted as the first-line treatment for acute promyelocytic leukemia (APL). Another arsenic compound named the Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine containing As4 S4 , has been shown to be highly effective in treating adult APL. In the treatment of pediatric APL, the safety and efficacy of RIF remains to be confirmed. This randomized, multicenter and noninferiority trial was conducted to determine whether intravenous ATO can be substituted by oral RIF in the treatment of pediatric APL...
August 30, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30157297/myeloproliferative-neoplasms-in-the-young-mayo-clinic-experience-with-361-patients-age-40-years-or-younger
#18
Natasha Szuber, Rangit R Vallapureddy, Domenico Penna, Terra L Lasho, Christy Finke, Curtis A Hanson, Rhett P Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Between 1967 and 2017, 361 patients with myeloproliferative neoplasms (MPN), age ≤40 years, were seen at our institution, constituting 12% of all MPN patients (n=3,023) seen during the same time period; disease-specific incidences were 12% in polycythemia vera (PV; n=79), 20% in essential thrombocythemia (ET; n=219) and 5% in primary myelofibrosis (PMF; n=63). Compared to their older counterparts, younger patients were more likely to present with low risk disease (P<0.001) and display female preponderance in ET (P=0...
August 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30156701/practice-relevant-demarcation-of-systemic-mastocytosis-associated-with-another-hematologic-neoplasm-sm-ahn
#19
LETTER
Ayalew Tefferi, Sahrish Shah, Terra L Lasho, Mrinal M Patnaik, Kaaren K Reichard, Curtis A Hanson, Rhett P Ketterling, Animesh Pardanani
No abstract text is available yet for this article.
August 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30152894/unilateral-purpura-resulting-from-deep-vein-thrombosis
#20
Jason A Freed, Andrew J Hale
No abstract text is available yet for this article.
August 28, 2018: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"